Introduction
============

Bone is a complex and dynamic tissue endowed with excellent regeneration capacity. However, large or unstable fractures are disadvantageous to successful healing and require additional treatments before they regenerate [@B1]. Tissue engineering uses specific three-dimensional (3D) structural biomaterials (generally known as "bone scaffolds") to replace and restore defects [@B2], [@B3] and to overcome the limitations of autogenous and allogenous grafts. Currently, by means of processing natural and synthetic biomaterials, scaffolds can be easily obtained and designed with different geometric shapes for bone defect healing [@B4]. In addition, to enhance bone regeneration, cells or drugs are added into scaffolds and are delivered to bone defect sites together. Excitingly, over the last few decades, RNA-based therapies have been increasingly used to repair bone defects, as the understanding of molecular mechanisms, such as gene regulation networks that include molecular triggers, signaling molecules, and transcriptional regulators etc. [@B5] and cellular processes that include endochondral ossification and intramembranous bone formation [@B6] has gradually increased.

A large variety of RNA therapeutics for bone regeneration have been developed based on the diverse family of RNA molecules, including messenger RNA (mRNA) [@B7], [@B8], microRNA (miRNA) [@B9]-[@B11], small interfering RNA (siRNA) [@B12], [@B13], and long noncoding RNA (lncRNA) [@B14]-[@B16]. Different RNA-based therapeutics, when combined with different scaffolds, can enhance bone defect repair at the RNA level through diverse mechanisms. For example, mRNA in the cytoplasm can be directly supplemented through several methods and then translated into additional therapeutic proteins **(Figure [1](#F1){ref-type="fig"}A)**. miRNA upregulates osteogenic-related genes or downregulates adverse genes at the posttranslational level **(Figure [1](#F1){ref-type="fig"}B)**. siRNA can be designed to silence a specific gene that inhibits bone formation through a particular endogenous pathway **(Figure [1](#F1){ref-type="fig"}C)**. The main mechanism of lncRNA involves the indirect regulation of genes through the binding of competing endogenous RNAs (ceRNAs) with miRNAs during osteogenesis [@B17]. However, the use of lncRNAs has been limited to exploration with a small number of transfected cells in bone tissue engineering and is therefore not described and discussed in detail in this review.

As molecular technology, nanotechnology and the use of novel biomaterials have advanced in the last few decades, therapeutic RNAs can be easily synthesized, delivered to bone and modified according to specific needs. Although naked RNA molecules have been used to repair bone-related disease [@B18], the instability of RNA has hindered its use. Therefore, modification of RNA is beneficial. Generally, two methods has been used to deliver RNA to bone tissue, namely, systemic delivery and local delivery to the bone sites. Two commonly applied methods of systemic delivery are viral vectors and nonviral nanoparticles. Local delivery to the bone defect site primarily utilizes nonviral biocompatible scaffolds, which offer intrinsic advantages but also show some disadvantages. Previous reviews [@B19]-[@B21] have summarized the applications of the loading of different types of RNAs onto/into scaffolds in bone tissue engineering.

However, no study has yet systematically summarized the roles of these RNA-based biomaterials in local delivery. Hence, this review will discuss the mechanisms of the three types of RNAs, namely, mRNA, miRNA, and siRNA, with an emphasis on the classification of these RNA delivery systems based on the different scaffolds used and the description of clinical trials and therapeutic applications of these RNA delivery biomaterials in the field of bone defect repair. In addition, the advantages and limitations of RNA therapies are discussed.

mRNA-based therapy for bone repair
==================================

mRNA preparation for bone defect repair
---------------------------------------

mRNA is a type of single-stranded ribonucleic acid that is transcribed from one strand of DNA, which functions as a template, and carries genetic information to direct protein synthesis in eukaryotic cells *in vivo* [@B22]. *In vitro* transcription mRNA (IVT mRNA), rather than endogenous mRNA, has tremendous potential to repair bone defects and represents a new drug class. The use of IVT mRNA avoids the obstruction of the nuclear membrane that occurs due to the transfection of plasmid DNA (pDNA), which is inefficient as a means of gene therapy. mRNA does not have to enter the nucleus to be effective, which not only avoids the barrier posed by the nuclear membrane [@B23] but also results in higher effectiveness in nonmitotic cells [@B24]. Moreover, there is no risk of genomic integration after introducing mRNA, and mRNA has no immunogenic CpG island motifs, unlike pDNA. These issues remain a major concern for DNA-based gene therapy [@B25], [@B26]. The excellent properties of mRNA ensure that high-efficiency, controlled and rapid onset of therapeutic proteins expression can be obtained by mRNA-based treatments. Transcription of mRNA *in vitro* requires mimicking of intracellular transcriptional environment. Generally, IVT mRNA is transcribed from a linearized pDNA or a polymerase chain reaction (PCR) template with a bacteriophage promoter, a 5´ untranslated region (UTR), an open reading frame (ORF), a 3´ UTR, and an optional poly\[d(A/T)\] sequence [@B23]. The instability of mRNA due to its inclusion of hydroxide radicals and surrounding nucleases has evoked some concerns. Undoubtedly, the inclusion of chemically modified nucleotides in the cap structure, 5´ or 3´ UTR, ORF, or other parts of the mRNA offer a desirable solution for ensuring the stability and translatability of an mRNA [@B7], [@B27], [@B28].

mRNA delivery to bone-related cells
-----------------------------------

### Physical methods

In 1969, mRNA was successfully transcribed *in vitro* for the first time [@B29]. This appeared to be useful for application to vaccines development, immunotherapy of cancer, and treatment of various other diseases [@B30]. Delivery of mRNA to the cytoplasm can be achieved by both physical methods (electrotransfection [@B31], a gene gun [@B32], or microinjection [@B33], [@B34]) and chemical methods (cationic polymers, liposomes, liposome nanoparticles, etc.). For example, electroporation is considered to be a highly effective physical method for the direct delivery of mRNA into the cytosol [@B31], [@B35], which is achieved *via* applying electrical pulses to the cell membrane so that mRNA can enter the cytoplasm. Nevertheless, until now, few studies have reported the use of these techniques in bone tissue engineering to achieve mRNA delivery due to the high cost and inconvenience of *in vivo* delivery.

### Chemical methods

Compared with physical methods, the applications of chemical methods have been widely explored in the repair of bone defects [@B36] due to their low cost, user friendliness, and multifunctionality. Among chemical carriers, cationic polymers, lipoplexes, and lipid nanoparticles have been used mainly in mRNA-based bone tissue engineering. For example, the cationic polymers poly-L-lysine (PLL) and polyethyleneimine (PEI) [@B7], [@B37], two typical types of cationic polymers with positive charges, can bind to negatively charged mRNA to form nanoparticles that can be absorbed by cells *via* the endocytosis. In terms of delivery into the cytoplasm, PEI is more efficient than PLL [@B38] that did not result in detectable translation of mRNA [@B36]. Another important vector is lipoplex nanoparticles (or their derivatives), which have been used for a wide variety of mRNA delivery methods [@B39]-[@B41]. After mixing nucleic acids (negative charges) with cationic liposomes (positive charges), these components will spontaneously assemble into multiphase complexes through electrostatic interactions [@B24]. Nanoparticles have assumed various forms, such as polyplexes, lipoplexes, lipid-nanoparticles (LNPs), dendrimers, inorganic nanoparticles, and hybrid nanoparticles [@B41]. In a recent study, researchers developed improved biodegradable lipid nanoparticles to deliver mRNA into the liver for CRISPR/Cas9 gene editing, which accurately altered the genetic code of cells with an efficiency as high as 90% [@B42]. In conclusion, lipoplex nanoparticles are the most effective mRNA delivery tools reported to date and may overcome many technical barriers. Other cationic polymers have been discussed in previous reviews [@B36], [@B43].

mRNA delivery to bone defect sites
----------------------------------

mRNA possesses superior properties for the preparation of tumor vaccines [@B44]-[@B48], cancer immunotherapy [@B49], drug delivery [@B50], skin repair [@B51], myocardial damage repair [@B52], and other fields of regenerative medicine. However, it was not until 2015 that the enormous potential of mRNA in bone tissue engineering was discovered by Elangovan et al. [@B7], who first used mRNA combined with tissue engineering scaffolds to repair bone defects and thereby opened a new avenue for bone regeneration.

### mRNA modification

Regardless of the field, one of the main limitations of mRNA applications is immunogenicity, as unmodified mRNA is recognized by innate immune sensors that activate genes that inhibit translation [@B53]. To reduce the immunogenicity of mRNA, Elangovan et al. [@B7] modified the ribonucleic acid triphosphates of the mRNA coding region by replacing guanosine and cytosine with thioglycosylated guanosine and methylated cytosine, and the modified mRNA was called cmRNA. As mentioned before, cmRNA has lower immunogenicity than unmodified or mRNA with 25% modification. Subsequently, a complex of bone morphogenetic protein-2 (BMP-2)-encoding cmRNA and PEI was combined with a collagen scaffold for the repair of a rat skull defect. As expected, the cmRNA-modified scaffolds significantly accelerated process of bone regeneration, while pDNA-modified scaffolds had limited effects on bone healing. By using this method, Elangovan et al. [@B7] perfectly demonstrated the powerful potential of cmRNA-modified scaffolds in bone tissue engineering by demonstrating the efficacy of cmRNA for such application. Based on this study, the Elangovan team members [@B37] further compared the promotion of regeneration in calvarial defects of rats by cmRNA encoding BMP-2 and cmRNA encoding BMP-9 after electrostatic interaction with the collagen scaffold. The osteoinductive capability of BMP-9-cmRNA was stronger than that of BMP-2-mRNA, which was contrary to common belief that BMP-2 is a useful therapeutic molecule in the clinic [@B54]. Certainly, their results lacked sufficient evidence to completely disprove the effectiveness of BMP-2. Subsequently, Zhang et al. [@B28] designed a new mRNA that deleted an upstream open-reading frame in the 5′-UTR and an AU-rich tract polyadenylation element in the 3′-UTR. 5-iodo-modified pyrimidine nucleotides were also introduced into the mRNA as a translation initiator for short UTRs (TISU), which show significant advantages in enhancing new bone formation.

### Vector improvement

The improved cmRNA appeared to have a lower immunogenicity. However, the release duration of mRNA, which is one of the key issues in affecting mRNA applications for bone regeneration, did not seem to be considered in previous research. Improving mRNA stability and prolonging its effects, even when it shows low immunogenicity, are still urgently needed. The Plank laboratory has focused on the research of advanced magnetic liposome transfection vectors [@B55]-[@B58]. On the one hand, it was assumed that using these advanced vectors with a high transfection efficiency to deliver osteogenic-related mRNA could promote bone formation in bone defect sites. On the other hand, the use of a linearized template resulted in difference in translation efficiencies compared to those of mRNAs with modified ribonucleic acid triphosphates. For example, a NotI-linearized template possessed a high translation efficiency compared to that of the XbaI-analogue reported by Elangovan and coworkers [@B7]. Under double remodeling, lipoplexes and magnetic lipoplexes were used to deliver enhanced-green fluorescent protein (eGFP)-cmRNA to rat adipose mesenchymal stem cells (AMSCs) or bone marrow mesenchymal stem cells (BMSCs) [@B27]. The results indicated the higher efficiency of the magnetic lipoplexes, which produced 1.5-fold increased fluorescence. The testing of alkaline phosphatase (ALP) activity and Alizarin Red staining (RAS) also showed that magnetofection was able to deliver human BMP-2 (hBMP-2)-cmRNA into the cytoplasm more efficiently in both AMSCs and BMSCs than lipofection. To detect the capacity for enhancing bone regeneration of these complexes *in vivo*, hBMP-2-cmRNAs/lipids were combined with fibrin gel scaffolds and implanted into noncritical femoral bone defects in rats. The hBMP-2-cmRNA/scaffolds were able to accelerate bone formation according to μ-computed tomography images and histomorphometric analysis after 2 weeks.

mRNA-based scaffolds improved bone regeneration
-----------------------------------------------

In tissue engineering, the stability and sustained release of loaded molecules are important when the scaffold is used to deliver small molecules. After initially confirming the superior potential of mRNA for bone tissue engineering, it was necessary to determine how to prepare stable and sustainable scaffolds to deliver mRNA. The scaffold parameters (such as biocompatibility, biodegradability, chemical composition, internal structure, pore size, and mechanical properties) should be designed to promote bone remodeling processes [@B58]. There are two main methods of gene transfer used for tissue regeneration. Mesenchymal stem cells (MSCs) are transfected with nucleotide molecules *in vitro* and subsequently transplanted into defect sites. Osteogenic gene-modified scaffolds are directly transplanted into defect sites to recruit MSCs *in vivo*. However, the latter method is more commonly used for mRNA-based therapy for bone regeneration **(Table [1](#T1){ref-type="table"})**. This section describes two typically mRNA-based scaffolds (fibrin gel scaffold and collagen scaffold) and discusses some extra-chemical components, such as calcium phosphate, that could be added to the scaffolds to enhance the formation of bone.

In addition to hydroxyapatite (HA), collagen accounts for a majority of bone tissue and has a complex structure [@B1]. Native collagen occurs in two forms: as a swollen hydrogel or as sparse fiber in a lattice-like organization. Collagen type I, as a raw material, is the type most commonly used [@B59] to fabricate scaffolds. For nonload-bearing bone defects such as those of the skull, collagen-like scaffolds are applied to simulate the composition of the original bone tissue because of their limited mechanical properties. Badieyan et al. [@B60] designed vacuum-dried collagen sponge scaffolds preloaded with complexes of cmRNA and lipids that could be associated with the scaffold through weak interactions to ensure a prolonged and sustained release for efficient transfection. In their study, after vacuum drying, the collagen sponge scaffolds possessed a closed structure that entrapped the cmRNA/lipids. Subsequently, the RNA complexes were released from the scaffolds during the gradual degradation of the collagen sponge scaffolds. The research results showed that the scaffolds could provide steady-state protein production for 11 days. In addition, Zhang et al. [@B28] prolonged the repair time *in vivo* in a similar scenario, which produced ameliorative repair effects for 8 weeks in critical-sized femoral defects in rats.

The stability and sustained release of such scaffolds also evoked the interest of Utzinger et al. [@B61] and Balmayor et al. [@B62]. Utzinger et al. [@B61] employed a scaffold that consists of calcium phosphate cement (CPC) wrapped around precoated erythropoietin (EPO)-cmRNA complexes composed of cmRNA and PLGA-based microparticles. The PLGA microparticles rapidly degrade to allow the ingrowth of cells. At the same time, the enhanced degradation produced the steady release of cmRNA complexes. Balmayor et al. [@B62] compared the rates of molecular release by fibrin gel and micro-macro biphasic calcium phosphate (MBCP) granules in a 3D culture environment after loading them with hBMP-2 cmRNA. First, compared to 2D cultures, the 3D fibrin gel and MBCP granules produced superior gene expression. Second, MBCP played a role in the fast release of cmRNA and decreased gene transfection efficiency, whereas the fibrin gel produced increased cellular internalization. Although these materials were developed for clinically employed materials, further modification of materials should be adopted for mRNA delivery well.

miRNA-based therapy for bone regeneration
=========================================

miRNA in biology
----------------

Since lin-4 and lin-7, two small noncoding RNAs, were discovered in succession approximately 20 years ago, thousands of miRNAs have been found to play important regulatory roles in organisms [@B64]. The miRNA is a short, approximately 22-ribonucleotide-long noncoding RNA that exerts vital regulatory functions at the posttranscriptional level of gene expression in multiple organisms *via* activating specific signaling pathways as an endogenous RNA [@B65]. Classically, the journey of miRNAs begins in the nucleus, where they are transcribed into long primary miRNAs (pri-miRNAs) with cervical-loop structures by RNA polymerase II. Afterwards, pri-miRNAs are recognized and processed by Drosha (a member of the RNase III enzyme family) into precursor miRNAs (pre-miRNAs) with a shorter nucleotide length [@B66]. Subsequently, the pre-miRNAs are transported from the nucleus to the cytoplasm through the nuclear pore and processed by Dicer (another member of the RNase III enzyme family) into mature miRNAs [@B67]. In general, miRNA functions *via* combining with the RNA-induced silencing complex (RISC) [@B68] to form a new silencing complex, termed miRISC. The miRISC recognizes and selectively targets certain areas of the 3′ UTR (or 5′ UTR) of mRNA, with which miRNA is complementary. It should be noted that pairing of miRISC and mRNA is not completely strict, and miRISC does not always target only one mRNA [@B69]. mRNA is not specifically regulated by miRISC [@B70], which reflects the numerous powerful gene regulatory networks that function in organisms. These networks are gradually being revealed.

Therefore, in each stage of the formation and functioning of mature miRNAs, the corresponding miRNA could be designed to regulate genes. On the one hand, to upregulate the target genes of miRNAs, antisense strands of miRNAs [@B71], [@B72], termed anti-miRNA, are mostly designed to combine with miRISC, resulting in the silencing of the complementary mature miRNA (or affecting the maturation of the miRNA). miRNA masks [@B73] are designed to recognize and coat the 3′ UTR (or 5′ UTR) of an mRNA to block the binding of the miRNA and mRNA, consequently resulting in an increase mRNA and protein expression. On the other hand, to downregulate a target gene, molecules that mimic the design of endogenous miRNAs, known as miR-mimics, can be used to degrade an mRNA or inhibit protein translation, which leads to a decrease in the target protein. In this section, the roles of miRNA in the field of bone defect therapy are described with a focus on the methods of miRNA delivery.

Role of miRNAs in bone defect repair
------------------------------------

MSCs, one of the most important seed cells for tissue engineering and regeneration, can be either preloaded onto/into the scaffolds after being modified with RNAs *in vitro* and then implanted into defect or be recruited to RNA-modified scaffolds implanted into defects *in vivo*. Moreover, important classical signaling pathways involved in regulating the osteogenic differentiation of MSCs, such as the BMP signaling pathway and the Wnt/β‐catenin signaling pathway [@B21], involve several members that can be regulated and influenced by each other or miRNAs as part of complex regulatory networks [@B74]. For example, in the BMP signaling pathway, NOG, the noggin protein gene, prevents the combination of BMP and its receptor to suppress osteogenic differentiation. miR-148b [@B75], [@B76] can target NOG to enhance the expression of BMP, while miR-146a [@B77], [@B78] binds with Smad4 (phosphorylated by complexes of BMP and its receptor (BMPIA, BPMLB or ALK2)) to suppress osteogenic differentiation. Therefore, an increase in Smad4 is produced by anti-miR-146a. miR-542-3p is a direct target of BMP-7 and function as an inhibitor [@B79]. In the Wnt/β-catenin signaling pathway, runt-related transcription factor 2 (Runx2), also known as core-binding factor A1 (Cbfa1), belongs to the Runx family and plays a role in the BMP signaling pathway as a master osteoblast transcription factor that can be regulated either directly or indirectly. For instance, miR-23a, miR-204 [@B80], miR-103a [@B81], and miR-467g [@B82] can directly target Runx2, leading to the repression of Runx2, while miR-135 targets Hoxa2, a negative regulator of Runx2, resulting in the enhancement of osteoblast differentiation [@B83]. Additional miRNA regulators are described in **Figure [2](#F2){ref-type="fig"},** and the regulatory effects of miRNAs on bone development *via* different processes are briefly summarized.

Although cell phenotype development requires the regulation of multiple miRNAs, some miRNAs have an opposite effect on the regulation of osteogenic differentiation in different cell types. miR-26a inhibited osteogenic differentiation of human adipose-derived stem cells (hASCs) *via* targeting Smad1 [@B84], while Trompeter et al. [@B85] showed that miR-26a accelerated osteogenic differentiation in unrestricted somatic stem cells from human cord blood. Chen et al. [@B71] reported that miR-34a inhibited the osteogenic differentiation of hMSCs and that anti-miR-34a was used to accelerate osteogenic differentiation *in vivo* in mice. However, Liu et al. [@B10] showed that miR-34a promoted bone regeneration by MSCs in rats *in vivo*. These heterogeneous functions have not yet been fully explored at the same time.

miRNA delivery to bone-related cells
------------------------------------

miRNAs (negatively charged) have been delivered to bone-related cells after binding with vectors (positively charged), such as cationic polymers and cationic liposomes. miRNAs can also be delivered *via* lipid-based vectors, polymer-based vectors (PLAG NPs), or inorganic-based vectors (bioactive glass nanoclusters or nanohydroxyapatite). Studies have shown that the size of the nucleic acid and the physical properties of the vector itself affect the efficiency of transfection. PEI [@B86], as a cationic polymer, is commonly used to deliver miRNA to the cytoplasm, while lipids and liposome analogues are most commonly applied to deliver miRNA to bone-related cells *in vitro*/*vivo*. These vectors have been studied in depth and are widely commercially available, including Oligofectamine [@B87], Lipofectamine 2000 [@B81], [@B88], [@B89], and Dharmafect 1/2/3/4 [@B90], [@B91]. In addition, to achieve optimal delivery efficiency, Qureshi [@B92] and Moncal [@B93] used silver NPs and therapeutic miRNA molecules to form photoactivated silver NPs that were combined by robust thiolate bonding and could be dissociated under a range of UV wavelengths from 350 to 450 nm, resulting in the controlled release of miRNA molecules. Increasing numbers of improved vectors have been exploited for the delivery of miRNA to cells, albeit with limited success in clinical trials, making further studies necessary.

miRNA-based scaffolds in bone defect sites
------------------------------------------

Although nano- and microparticles have been synthesized to systematically load miRNAs, these particles are rapidly cleared away from the desired sites after injection *in vivo* due to their small size and discontinuous release. Hence, collagen scaffolds, solid porous scaffolds and hydrogel scaffolds have been developed to release miRNA locally to surrounding cells as they can provide a platform for cell migration, adhesion and differentiation. Therefore, the miRNA-scaffold method is a better method, which has been proven by several studies. Unlike cell-free scaffolds, which are mostly utilized to deliver mRNAs in mRNA therapy, cell-free and cell-mediated scaffolds have both been applied to miRNA delivery. Cell-free scaffold-loaded miRNA/vector complexes are implanted into bone defect sites, termed "*in situ* delivery". In contrast, for *ex situ* delivery, rat/human BMSCs or AMSCs are transfected with therapeutic miRNAs *in vitro*, loaded onto scaffolds, and ultimately implanted into the damaged areas **(Figure [3](#F3){ref-type="fig"})**.

A variety of scaffolds have been used to facilitate the delivery of miRNA. However, some types of scaffolds loaded with nonviral vectors or cells are more commonly applied in bone regeneration, including hydrogel-based scaffolds, HA scaffolds and collagen-based scaffolds. These scaffolds are summarized in **Table [2](#T2){ref-type="table"},** and their applications are reviewed in more detail.

### Hydrogel scaffolds

Hydrogels are highly hydrophilic materials and ideal for clinical application [@B94]. Injectable hydrogels can be used for many types of geometrical deformities and are more advantageous compared with prefabricated scaffolds [@B95]. According to previous studies, many types of hydrogels can encapsulate miRNA-processed cells for local delivery with high viability [@B86], [@B96], [@B97], and those processed cells are designed to promote bone formation. Nguyen et al. [@B86] proved the ability of encapsulated miR-20a to process human MSCs (hMSCs) within polyethylene glycol (PEG) hydrogels. These hMSCs (posttransfection)-loaded PEG hydrogel scaffolds were applied to the repair of critical-sized calvarial defects in rats [@B13], resulting in good bone repair. Instead of using conventional biomaterial vectors, Xue et al. [@B97] used positively charged bioactive glass nanoclusters (BGNCs) with ameliorative ultra-large mesopores as ideal miRNA vectors. The BGNCs possess gene activation properties when they are delivered to bone with miRNA. Similar to that observed for cationic polymers, there is a strong electrostatic interaction between the negatively charged phosphate groups in miRNA and the positively charged calcium ions in BGNCs. In addition, hydrogels can deliver miRNA/vector complexes without cells to bone defects in a controllable way [@B98], [@B99]. Cell-free scaffolds are the ultimate goal of tissue engineering due to their ease of use, lower costs and lack of complications in clinical regeneration [@B100]. A two-stage release system was designed to prolong the expression of miR-26a by Zhang et al. [@B98]. PLGA microspheres, containing complexes of miR-26a/hyperbranched polymer (HP) vectors, were encased in PLLA scaffolds, which ensured sufficient time for the transfection of endogenous cells and resulted in a good repair effect. Similarly, anti-miRNA-138/chitosan (CS) nanoparticle (NP) complexes were encapsulated in β-sodium glycerol phosphate (GP) hydrogel scaffolds for controlled release *in situ* by Wu et al. [@B99]. The effect of the anti-miR-138 CS/GP scaffolds was barely adequate and this idea needs to be further explored.

### Collagen-based scaffolds

Similar to mRNA-based therapeutics, collagen, as the major organic component of the bone extracellular matrix, plays an important role in the delivery of miRNA for bone regeneration. Conventional collagen scaffolds are prepared using type I collagen, which can be formed into a variety of shapes to treat various defects, such as disciform scaffolds for critical-sized calvarial defect. In addition, collagen scaffold can be generated by 3D printing with collagen as bioink [@B93]. As a novel technology, 3D printing can precisely control the biomechanical properties, macrostructures (such as pore size and shape) and microstructure (such as roughness) of scaffolds [@B101], [@B102] to meet patient-specific demands with simplified procedures specially. 3D printed scaffolds were loaded with miRNA-transfected cells and applied to bone defect sites, resulting in successful bone healing [@B93]. This method can also be applied to deliver mRNA and siRNA through the loading of mRNA- or siRNA-treated stem cells. However, few studies have reported the use of cell-free 3D printed scaffold loaded RNAs (regardless of which types of RNAs were used) for the repair of bone defects.

As a derivative of collagen, atelocollagen is obtained by removing the collagen terminal peptide with pepsin digestion. High-purity atelocollagen has decreased antigenicity and increased bioaffinity; therefore, it is considered a good choice for bone regeneration. Yoshizuka (Yoshizuka et al., 2016) [@B72] demonstrated its outstanding effects in a refractory fracture model.

### HA-based scaffolds

Based on previous results, HA accounts for 70% of bone composition and provides mechanical support for the body [@B103]. When it is added to hydrogel or collagen, HA enhances the mechanical properties of composite scaffolds. In general, HA alone can form a scaffold [@B104], and HA and tricalcium phosphate (TCP) can form a composite biomaterial [@B9], [@B71], [@B105]. Sometimes, HA, in the form of nano HA (nHA), can form composite scaffolds together with collagen or CS for use in miRNA delivery [@B106]-[@B107]. Unlike previous methods that encapsulated miRNAs in liposomes, nHA can directly carry miRNAs in combination with other components to form a composite scaffold. Interestingly, HA-based scaffolds are commonly used to detect ectopic bone formation under the endothelium *in vivo*.

siRNA-based therapy for bone repair
===================================

siRNAs in biology
-----------------

Endogenous siRNAs are short (19-30 nucleotides) double-stranded RNAs (dsRNAs) with two nucleotide-overhangs in the 3\' UTR [@B115]. Unlike IVT mRNAs, which function as a supplement to endogenous mRNAs, siRNAs play a role in cells as regulators and share some similarities with miRNAs. For example, both have similar physicochemical properties, and the mechanism of siRNA is the same as that of miRNA mimics. siRNA is derived from long dsRNA (without cervical-loop structures) in the cell *via* cleavage of long dsRNA by Dicer into siRNA. Subsequently, siRNA selectively targets and ultimately degrades complementary mRNA after being combined with RISC in the cytosol. However, unlike miRNAs, which show a different regulatory pattern, siRNAs function only to silence gene pathways. In addition, siRNA is fully complementary to mRNA [@B116], whereas miRNA is partially complementary to mRNA. Furthermore, siRNA is highly specific, and each type of siRNA targets only its complementary mRNA, while one type of miRNA can bind with multiple species of mRNA at the same time, and multiple mRNAs can target the same mRNA nucleotide sequence. This shows the specificity and high efficiency of siRNA in applications. siRNA and miRNA together are known as RNA interference (RNAi) [@B117], which leads to a highly efficient posttranscriptional gene silencing process in most eukaryotic cells. In RNAi therapy, siRNAs are synthesized *in vitro* and delivered into the cytoplasm, where they ultimately function as endogenous Dicer-cleaving products to degrade mRNA. In 2001, 21-nucleotide-long synthetic siRNAs were first successfully transfected into mammalian cells, resulting in successful gene silencing in transfected cells in studies by Tuschl and Gore [@B118]; this provided new ideas for the treatment of numerous diseases such as ocular diseases, lung infections, skin diseases and cancer. Unmistakably, siRNA also plays an important role in bone regeneration, and its application will be discussed in detail in the following.

siRNA in bone defect repair
---------------------------

In some studies, siRNA has been applied to silence a specific gene that inhibits the formation of osteocytes or facilitates the formation of osteoclasts with high specificity, which is a high efficiency method for bone defect repair. Earlier, scholars explored negative regulators of osteogenic differentiation to lay the foundation for later research. Kato et al [@B119] reported that silencing S100A4, a bone-related gene, could upregulate osteoblastic differentiation. Zhao and Ding [@B120] identified the main osteogenic suppressors in human mesenchymal stem cells through a high-throughput siRNA library screen, such as guanine nucleotide-binding protein (G protein) alpha subunit 1 (GNAS1). Cheema et al. [@B121] further proved that knocking out GNAS1 led to increased osteoblastic differentiation. Silencing the gene NOG with siRNA (siRNA-Noggin) enhanced the expression of BMP in cells [@B12]. Tumor necrosis factor α (TNF-α) [@B122], casein kinase-2 interacting protein-1 (Ckip-1) [@B123], soluble VEGF receptor 1 (sFlt-1) [@B124], pleckstrin homology domain-containing family O member 1 (Plekho1) [@B125], WW domain-containing E3 ubiquitin protein ligase 1 (Wwp1) [@B126] and receptor activator of nuclear factor kappa B (RANK) [@B127] are negative regulators of bone formation and have been used as a target genes of siRNA silencing for bone regeneration.

siRNA delivery to bone-related cells
------------------------------------

Because siRNAs are vulnerable ribonucleotide strands, the delivery of naked siRNAs is less than ideal. Lipid-based transfection reagents, such as Lipofectamine 2000, are commonly used to deliver siRNA to cells. However, some highly differentiated cells, such as primary human osteoclasts, are hard to transfect, so more effective lipid carriers have been explored. Selinger [@B128] used FuGENE 6, an analogue of Lipofectamine 2000, for delivery to primary human osteoclasts; which was more efficient than using Lipofectamine 2000. In addition, Wang et al. [@B129] used biodegradable polyethylenimine (PEI-Et) to address the fact that PEI (PEI 25 kDa) lacks degradable linkages, which makes it too toxic for clinical applications. Due to the increase in bioindustry, various optimized siRNA-specific transfection reagents can be obtained commercially, including oligofectamine kits [@B119], the Xtreme-siRNA transfection reagent [@B120], 98N12(5) lipidoid [@B130], and the Ambion siPortTM Amine Transfection Agent [@B131]. Therefore, for efficient delivery of siRNA to cells, the abovementioned reagents could be used. However, cell-free scaffolds need better optimized vectors to combinie siRNA in the complex environment of the body. Some synthetic copolymers are used in therapeutic devices with biocompatible and biodegradable properties to encapsulate siRNAs and release them in a controlled manner *in vitro* or *in vivo*. PLGA microparticles blended with PEI [@B127], [@B132], [@B133], PEG blended with PEI [@B12], [@B85], and poly-D-L-lactic acid (PLA) blended with PEI NPs [@B130] have been utilized to ameliorate the cytotoxicity of PEI. These carriers have been synthesized to deliver siRNA to cells on scaffolds, which is described in the vector part of **Table [3](#T3){ref-type="table"}**.

siRNA-based scaffolds in bone defect sites
------------------------------------------

In early studies of the delivery of siRNA to localized sites of interest *in vivo*, electroporation was used to deliver siRNA to cells [@B12], [@B134], which may result in electrical damage to cells. In contrast, chemical substances provide a milder means of delivery. Compared with mRNA and miRNA, siRNA applied in bone repair utilizes two very common delivery methods: systemic delivery for bone repair of osteoporosis and local scaffold-based delivery for bone defect repair. Bisphosphonate [@B135], (Asp)~8~ or (Asp)~6~ oligopeptide [@B136], [@B137], (AspSerSer)~6~ oligopeptide [@B138] and CH6 aptamer [@B125] have a high affinity for hydroxyapatite, which can be exploited for carrying siRNAs specifically to bone-formation surfaces to silence genes that facilitate osteoporotic phenotype. Functionalized molecules were combined with lipid NPs (LNPs), PLGA NPs or PEG NPs and then delivered to osteoporosis sites *via* intravenous injection for the recovery of bone loss in ovariectomized (OVX) rodent species. For bone defect repairing, local scaffold-based siRNA delivery has greater advantages because of its organ specificity, decreased drug dose accumulation, excellent bone tissue penetration, and cellular internalization in bone defect sites. siRNA scaffolds are summarized in **Table [3](#T3){ref-type="table"}**. Hydrogel-, collagen- and CS-based scaffolds are popular choices for the delivery of siRNA as they are biodegradable, biocompatible, and able to entrap siRNA in the desired site for sufficient silencing time. The methods of delivering siRNA to bone defect sites with these scaffolds have been realized *via* cell-loaded scaffolds and cell-free scaffolds, which are the same with methods of delivery mRNA and miRNA, as shown in **Figure [3](#F3){ref-type="fig"}**. Interestingly, injectable CPC-augmented matrix scaffolds could continuously release siRNA over 50 days, as shown in a study by Wang et al. [@B132]; however, data on the silencing efficiency over such a long release time are unavailable. Nguyen [@B139] showed the silencing effect of photocrosslinked dextran (DEX) hydrogel over 11 days. In view of the slowness of bone repair, the extension of the effective time of siRNAs is still worth exploring.

Co-delivery of RNAs
===================

The individual delivery of mRNA, miRNA, or siRNA has been described in numerous studies. In some cases, the delivery of multiple RNAs would achieve the suppression of undesirable proteins (*via* siRNA or miRNA) and the expression of desirable proteins (*via* mRNA or miRNA) [@B145] at the same time. The molecular weights and structures of miRNA (\~25 kDa) and siRNA (\~23 kDa) are similar [@B116], whereas mRNA is a 600-10,000-kDa nucleotide. Hence, a single biomaterial, containing both miRNA and siRNA is more suitable, although co-delivery with mRNA is more complex. Ball et al. [@B145] showed that the efficiency of using ionizable LNPs for co-delivering siRNA and mRNA could be improved by adjusting the proportions of the components (lipids, cholesterol, helper lipid and PEG) in the delivery vehicle. In addition, the ratio of the concentration of the siRNA and mRNA also affects the final internalization.

It is worth noting that the similar chemical properties of negatively charged nucleotides (DNAs or RNAs) simplifies the design of their delivery materials, but their co-delivery with proteins or drugs requires different designs according to the relevant physicochemical properties. For instance, PLGA NPs are positively charged on the surface after being modified with PEI, which could applied to the co-delivery of gene-gene, gene-protein or gene-drug combinations [@B146]-[@B149]. The surfaces of PLGA NPs gained a positive charge after pretreatment with PEI. The modifying surface particles that were conjugated with SOX 9 pDNA and Cbfa-1 siRNA were subsequently co-transfected into hMSCs to enhance cartilage differentiation [@B147]. As a result, both SOX 9 pDNA and Cbfa-1 siRNA were linked to the outer surface of the positively charged spheres through electrostatic interactions. In contrast, for co-delivery of RNAs and proteins to hMSCs, Cbfa-1 siRNAs were loaded onto the outer surfaces of PLGA NPs, whereas the SOX 9 protein was encapsulated into the particles [@B148]. To induce osteogenic differentiation of hMSCs, Park et al. [@B150] used PLGA NPs encapsulating Runx2 protein and coated with BMP-2 pDNA. Besides PLGA NPs, cationic sterosomes [@B151], quantum dots (modified with β-cyclodextrin and Cys-Lys-Lys-Arg-Gly-Asp (CKKRGD) peptide) nanocarriers [@B152] and polymeric micelles [@B153] were exploited to co-deliver RNAs and drug molecules that promote bone healing (such as dexamethasone and simvastatin) *via* electrostatic or hydrophobic interactions to induce the osteogenic differentiation of MSCs.

Advantages and disadvantages of using scaffolds for RNA delivery
================================================================

The scaffold matrix provides not only a delivery platform for drugs, proteins or other reparative factors but also a structural support for infiltrating cells during bone regeneration. However, high dosing strategies require consideration of the fact that long-term production of therapeutic proteins is still needed at the desired sites. Efforts to repair injured bone *via* gene-enhanced scaffold matrixes began in the 1990s [@B154], and these matrixes could retain the expression of the gene for at least 6 weeks after implantation into osseous defects; this was applied for RNA-based bone regeneration. RNA-enhanced scaffolds, as reservoirs of RNAs, locally deliver RNA complexes to sites of interest to avoid unwanted release in other sites by using economical methods. Moreover, *via* degradation by hydrolytic or biological enzymes, scaffolds could be spatiotemporal release small molecules in a controlled manner [@B155]. Encouragingly, numerous scaffolds have been designed to prolong the release time of RNAs [@B132], [@B139]. Another important advantage of scaffolds used for RNA delivery is that scaffolds can protect RNA complexes from serum nucleases or other biological enzymes to prevent physiological degradation to provide long-term, high-efficiency therapy *in vivo* [@B60], [@B126].

However, the uncertainty of the scaffold degradation rate and the specific parameters of the RNAs released from the scaffolds affect the efficacy of the RNAs. Sometimes, the strong interactions between scaffolds and vectors can limit the release of RNAs. Therefore, the coimmobilization of vectors and cells in scaffolds to facilitate the effective cellular internalization of infiltrating cells *in situ* is challenging. In addition, weak electrostatic interactions or biodegradable linkages between RNA/vector complexes and scaffolds could be used to control the delivery of RNA/vector complexes. Although existing research findings show that methods for the controlled release of RNAs from scaffolds over an extended time period have been continuously improved *in vitro*, few studies have been able to achieve long-term controlled release of RNAs from scaffolds and effective function of RNAs in targeted cells *in vivo*, which are the major limitations of RNA-based therapy for clinical bone remodeling.

Conclusions and perspectives
============================

Recently, RNA-based treatment methods have evoked intense interest for application to the treatment of numerous diseases because of the specific advantages of RNA [@B156]. RNA-based scaffolds for bone regeneration were discussed and summarized in this review, emphasizing the use of RNA to promote osteogenesis as therapeutic molecules loaded onto/into scaffolds. Among various biomaterials designed for the protection and delivery of RNAs, LNPs and polymer NPs are the main vectors used for carrying RNAs, and hydrogel and collagen are the most common scaffold materials used for the delivery of RNA complexes to bone sites *in vivo*. However, the use of RNA-based therapy in bone regeneration is still in its infancy and should be further addressed to meet clinical needs. First, bone repair is a long and complex process. Various injuries or different degrees of damage could lead to different healing effects in the clinic [@B157], which would present additional challenges for the successful utilization of RNA-based therapy. In addition, the effect the physical environment (mechanical properties, degree of roughness, concentrations of components, and the macro-shapes of scaffolds) and chemical factors (e.g., environmental pH) are important for bone remodeling processes during scaffold-based therapy for bone repair. However, these specific parameters were not explored during recent studies. For example, our previous study proved that difference in stiffness affect the osteogenic differentiation of MSCs in a 3D culture environment [@B158]. How do differences in stiffness affect delivery of RNAs? If such factors play a role in the release and transfection of RNAs, they would facilitate the development of RNA-loaded scaffolds for superior treatment. Second, it has been shown that RNAs could be stably released for more than 50 days *in vitro* [@B132]. The RNA delivery system tested by single cell line was available *in vitro*, but was not easy *in vivo*. Moreover, the long-term sustained release of RNAs is not equivalent to the long-term transfection of RNAs. Therefore, the extension of the effective time *in vivo* is still worth exploring. Finally, although many RNA delivery scaffolds have been explored for curing bone injury, a low-cost, wide-ranging and effective preparation method for RNA-based scaffolds has not yet been established. To facilitate the development of commercialized scaffolds, 3D printing technology might be introduced to fabricate RNA-based scaffolds. Moreover, some nanocarriers, e.g., AuNPs [@B159], may be considered for the loading of RNAs, which could draw lessons from the use of biomaterials in cancer drug delivery for successful bone defect healing.
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![**Schematic of the mechanisms of nonviral RNA therapy in cells. (A)** An mRNA is delivered into the cytoplasm and then translated into the corresponding protein *via* endogenous mRNA translation. **(B)** Three typical types of miRNAs are delivered to cells. An miRNA mimic enters the cell and acts similar to a normal intracellular miRNA. Anti-miRNA, which is an antisense strand of miRNA, combines with miRISC after delivery to cells resulting in the silencing of complementary mature miRNA and further increases in the translation of the corresponding mRNA. An miRNA mask can bind to the 3´ UTR of an mRNA to prevent the function of miRNA. **(C)** Delivery of siRNA utilizes a similar pathway as that of an miRNA mimic.**Abbreviations:** pre-miRNA: precursor miRNA; pri-miRNA: primary miRNA; RISC: RNA-induced silencing complex; tRNA: transfer RNA.](thnov10p3190g001){#F1}

![Schematic diagram of miRNA-regulated osteogenic differentiation *via* miRNA scaffold-based therapy. Green indicates upregulation and red indicates downregulation.**Abbreviations:** BMP: bone morphogenetic protein; ERK: extracellular regulated protein kinases; FAK: focal adhesion kinase; Gsk-3β: glycogen synthase kinase; HDAC6: histone deacetylase 6; Hes: hairy enhancer of split; Hey: Hes-related with YRPW motif; Hoxa 10/2: homeobox a10/2; NOG: noggin; Osx: osterix; PI3K/AKT: phosphatidylinositol 3-kinase/protein kinase B; Runx2: runt-related transcription factor 2; Satb2: special AT-rich sequence-binding protein 1; Smad: drosophila mothers against decapentaplegic; TAG1: transient axonal glycoprotein 1.](thnov10p3190g002){#F2}

![Schematic diagram of RNA-based scaffolds used for bone regeneration. For delivery of nucleic acid molecules, different RNAs were combined with vectors (such as lipids, polymers or others) with or without transfecting MSCs **(A)**. The cell-free scaffolds shown in the red dashed rectangle **(B)** and the cell-loaded scaffolds shown in the orange dashed rectangle **(B)** were designed (*in vitro*) to repair bone defects *in vivo* **(C)**.](thnov10p3190g003){#F3}

###### 

List of mRNA-based scaffolds for bone healing

  Scaffolds                  Gene                         Vector                                                           Implantation                                     Time                        Ref        
  -------------------------- ---------------------------- ---------------------------------------------------------------- ------------------------------------------------ --------------------------- ---------- ----
  **Hydrogel**               CPC/PLGA microsphere         EPO-cmRNA                                                        Lipoplexes                                       *In vitro*                  4 days     61
  Fibrin gel scaffold        BMP-2-cmRNA                  Micro-macro biphasic calcium phosphate (MBCP) ceramic granules   *In vitro*                                       3 weeks                     62         
  Fibrin gel scaffold        hBMP-2-cmRNA                 Lipoplexes                                                       Non-critical femoral bone defect model in rats   2 weeks                     27         
  **Collagen**               Collagen scaffold            BMP-2-cmRNA                                                      Polyethylenimine (PEI)                           Calvarial defects in rats   4 weeks    7
  Collagen sponge scaffold   BMP-2-cmRNA                  Lipoplexes                                                       Critical-sized mid-femoral defect in rats        8 weeks                     28         
  Collagen scaffold          BMP-2-cmRNA or BMP-9-cmRNA   PEI                                                              Critical-sized defects in rats                   4 weeks                     37         
  Collagen sponge scaffold   hBMP-2-cmRNA                 Lipofectamine 2000                                               Non-critical femoral bone defect model in rats   2 weeks                     60         
  **Other**                  Sheep and porcine tissue     Luciferase-cmRNA                                                 Lipoplexes/mag-lipoplexes                        *In vitro*                  24 hours   63

**Abbreviations**: PLGA: poly (lactic-co-glycolic acid)

###### 

List of miRNA-based scaffolds for bone healing

  Scaffolds                                                                       Gene                                                       Vector                                  Implantation                               Time                                       Ref        
  ------------------------------------------------------------------------------- ---------------------------------------------------------- --------------------------------------- ------------------------------------------ ------------------------------------------ ---------- ----
  **Hydrogel**                                                                    hMSCs loaded PEG hydrogel                                  miRNA-20a                               PEI                                        *In vitro*                                 4 weeks    86
  MAO Ti surface                                                                  miR-21                                                     CS/hyaluronic acid NPs                  *In vitro*                                 4 weeks                                    109        
  Gel culture plate                                                               miR-21                                                     CS/hyaluronic acid NPs                  *In vitro*                                 4 weeks                                    110        
  CS/TPP/ hyaluronic acid NPs                                                     Anti-miR-138                                               CS/TPP/hyaluronic acid NPs              *In vitro*                                 3 weeks                                    111        
  Injection biomedical fbrin glue hydrogel mixed with BMSCs (post-transfection)   miR-5106                                                   BGNCs                                   Critical-sized calvarial defect in rats    4 weeks                                    97         
  PLLA scaffold                                                                   miR-26a                                                    HP vector-PLGA microsphere              Critical-sized calvarial bone in mouse     8 weeks                                    98         
  GP hydrogel scaffold                                                            Anti-miR-138                                               CS NPs                                  Critical-sized calvarial defect in rats    8 weeks                                    99         
  miR-335-5p-transfected BMSCs loaded-silk sacffold                               miR-335-5p                                                 Lipidoid nanoparticles                  Critical-sized calvarial bone in mouse     5 weeks                                    112        
  **Collagen**                                                                    BMSCs (post-transfection) loaded collagen-based hydrogel   miR-34a                                 Lipofectamine 2000                         The tibial defect model in rats            8 weeks    10
  Atelocollagen scaffold                                                          Anti-miR-222                                               Lipofectamine                           The refractory fracture model in rats      8 weeks                                    72         
  BMSCs (post-transfection) loaded collagen scaffold                              miR-148b                                                   Silver NPs                              Critical-sized calvarial defect in rats    8 weeks                                    93         
  **HA**                                                                          Transfected hMSCs loaded on HA/TCP ceramic powder          Anti-miR-138                            Lipofectamine 2000                         s.c. in mouse for ectopic bone formation   8 weeks    9
  Transfected hMSCs loaded HA/TCP scaffold                                        Anti-miR-34a                                               Lipofectamine 2000                      s.c. in mouse for ectopic bone formation   8 weeks                                    71         
  ASCs (post-transfection) loaded porous HA scaffold                              miR-26a                                                    Lipofectamine 2000                      The tibial defect model in rats            12 weeks                                   104        
  Transfected hMSCs loaded on HA/TCP scaffold                                     Anti-miR-138, anti-miR-432 or anti-miR-222                 Lipofectamine 2000                      s.c. in mouse for ectopic bone formation   8 weeks                                    105        
  Collagen-nHA scaffold                                                           Dy547-labeled miRNA                                        nHA                                     *In vitro*                                 1 week                                     106        
  Collagen-nHA scaffold                                                           Anti-miR-133a                                              nHA                                     *In vitro*                                 4 weeks                                    107        
  Collagen-nHA scaffold                                                           miR-16                                                     nHA                                     *In vitro*                                 4 weeks                                    108        
  CS/nHA/nano-zirconium dioxide scaffold                                          miR-590-5p                                                 The X-treme gene transfection reagent   *In vitro*                                 1 week                                     113        
  **Others**                                                                      PCL scaffold                                               miR-148b                                Silver NPs                                 Critical-sized calvarial bone in mouse     12 weeks   91
  PCL scaffold                                                                    Anti-miR-432 or anti-miR-222                               Lipofectamine 2000                      *In vitro*                                 2 weeks                                    105        
  BMMSCs sheet                                                                    miR-122                                                    Micro/macro titanium oxide              *In vitro*                                 8 weeks                                    114        

**Abbreviations**: BGNCs: bioactive glass nanoclusters; CS: chitosan; GP: β-sodium glycerol phosphate; HA/TCP: hydroxyapatite/tricalcium phosphate; HP: hyperbranched polymer; MAO: microarc oxidation; nHA: coll-nano hydroxyapatite; PCL: polycaprolactone; PEG: polyethylene glycol; PLLA: poly-l-lactide; TPP: tripolyphosphate.

###### 

List of siRNA-based scaffolds for bone healing

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Scaffolds                                              Gene                             Vector                            Implantation                                                         Time                                                                     Ref        
  ------------------------------------------------------ -------------------------------- --------------------------------- -------------------------------------------------------------------- ------------------------------------------------------------------------ ---------- -----
  Hydrogel                                               PEG hydrogel scaffolds           siRNA                             PEI                                                                  *In vitro*                                                               4 weeks    87

  Injectable CPC augmentation matrix scaffolds           siRNA-RANK                       PLGA microparticles               *In vitro*                                                           12 days                                                                  132        

  DEX hydrogel scaffolds                                 siRNA-GFP                        PEI                               *In vitro*                                                           17 days                                                                  139        

  Dual-crosslinked photodegradable hydrogels scaffolds   siRNA-Noggin                     PEI                               *In vitro*                                                           2 weeks                                                                  140        

  Fibrin hydrogel scaffolds                              siRNA-Noggin                     Lipofectamine 2000                *In vitro*                                                           48 hours                                                                 141        

  PEG hydrogel scaffolds                                 siRNA-Noggin                     PEI                               Calvarial bone defect model in rats                                  12 weeks                                                                 13         

  SFCS scaffolds                                         siRNA-GNAS1\                     siPort amine transfection agent   Subcutaneous transplantation for ectopic bone formation              10 weeks                                                                 130        
                                                         siRNA-PHD2                                                                                                                                                                                                                  

  PLA-DX-PEG pellet                                      siRNA-Noggin                     PLA-DX-PEG polymer                The left dorsal muscle pouches of mouse for ectopic bone formation   7 days                                                                   142        

  PLGA-PEG-PLA-DM hydrogel scaffolds                     siRNA-Cy5                        Polymer diblock NPs               Femur fracture model                                                 4 weeks                                                                  143        

  PLLA scaffolds                                         siRNA-Sema4d                     Asp8-Stearyl-R8                   Femoral defect model in OVX rats                                     8 weeks                                                                  144        

  Collagen                                               Collagen sponge disk scaffolds   siRNA-Noggin                      Lipofectamine 2000 (*in vitro*) Electroporation (*in vivo*)          Dorsal muscular tissue in the Male ICR mice for ectopic bone induction   2 weeks    12

  CS                                                     CS sponge scaffolds              siRNA-Ckip-1 and siRNA-Flt-1      Lipofectamine™ 2000                                                  Calvarial bone defect model in rats                                      12 weeks   124
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** Ckip-1: casein kinase 2 interaction protein 1; CPC: calcium phosphatecement; DEX: dextran; Flt-1: soluble VEGF receptor 1; GFP: green fluorescent protein; GNAS1: guanine nucleotide-binding protein alpha subunit 1; PEG-PLA-DM : poly(ethylene glycol)-poly(lactic acid)-dimethacrylate; PEI: polyetherimide; PHD2: prolyl hydroxylase domaincontaining protein 2; PLA-DX-PEG: poly-D,L-lactic acid-p-dioxanonepolyethylene glycol block co-polymer; PLLA: poly-L-lactic acid; SFCS: silk fibroin-chitosan.
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